Veracyte, Inc. (VCYT)
Automate Your Wheel Strategy on VCYT
With Tiblio's Option Bot, you can configure your own wheel strategy including VCYT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VCYT
- Rev/Share 5.9388
- Book/Share 15.3141
- PB 1.7605
- Debt/Equity 0.0423
- CurrentRatio 5.1002
- ROIC 0.0179
- MktCap 2111361616.0
- FreeCF/Share 1.0054
- PFCF 26.9128
- PE 63.6522
- Debt/Assets 0.0384
- DivYield 0
- ROE 0.0283
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VCYT | Craig Hallum | -- | Buy | -- | $45 | March 20, 2025 |
| Downgrade | VCYT | Goldman | Buy | Neutral | $38 | $37 | Dec. 5, 2024 |
| Initiation | VCYT | UBS | -- | Buy | -- | $43 | Oct. 16, 2024 |
| Initiation | VCYT | Guggenheim | -- | Buy | -- | $40 | Oct. 10, 2024 |
News
Veracyte to Participate in Upcoming Investor Conferences
Published: May 20, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Blair 45th Annual Growth Stock Conference – Chicago, IL Presentation on June 3rd at 5:40 p.m. Eastern Time Jefferies Global Healthcare Conference – New York, NY Presentation on June 4th at 2:00 p.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte'.
Read More
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Read More
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
Read More
What Makes Veracyte (VCYT) a New Buy Stock
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer John Leite - Chief Commercial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Andrew Brackmann - William Blair Puneet Souda - Leerink Partners Colleen Babington - Wolfe Research Tejas Savant - Morgan Stanley Thomas DeBourcy - Nephron Research Sung Ji Nam - Scotiabank Operator Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2025 Financial Results Webcast.
Read More
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago.
Read More
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here's Why Veracyte (VCYT) is a Strong Growth Stock
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
Read More
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Read More
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Veracyte, Inc. (NASDAQ:VCYT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research, LLC Mason Carrico - Stephens Inc. Puneet Souda - Leerink Partners Maggie Boeye - William Blair & Company Lu Li - UBS Group AG Corey Rosenbaum - Scotiabank Subbu Nambi - Guggenheim Securities, LLC Yuko Oku - Morgan Stanley Joseph Conway - Needham & Company, LLC Prashant Kota - Goldman Sachs Operator Good day, and …
Read More
Veracyte to Participate in Upcoming Investor Conferences
Published: February 19, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 46th Annual Institutional Investors Conference – Orlando, FL Presentation on March 5th at 9:50 a.m. Eastern Time Leerink Partners Global Healthcare Conference – Miami, FL Fireside Chat on March 11th at 8:40 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by.
Read More
New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research.
Read More
Best Momentum Stocks to Buy for February 13th
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
VCYT and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 13, 2025.
Read More
New Strong Buy Stocks for February 13th
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
Read More
About Veracyte, Inc. (VCYT)
- IPO Date 2013-10-30
- Website https://www.veracyte.com
- Industry Biotechnology
- CEO Mr. Marc A. Stapley
- Employees 824